BioMarin licenses investigational Fabry disease therapy

BioMarin Pharmaceutical has entered an exclusive worldwide license agreement with GC Biopharma and Hanmi Pharm to develop and commercialize HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease.

Thepharmaletter reported the agreement, which brings the three companies together around the development and commercialization of the investigational therapy. The arrangement is described as exclusive and worldwide.

License agreement covers HM15421/GC1134A

According to Thepharmaletter, HM15421/GC1134A is an investigational long-acting enzyme replacement therapy for Fabry disease. BioMarin announced that it entered the license agreement with GC Biopharma and Hanmi Pharm.

The reported scope of the agreement covers development and commercialization. Thepharmaletter identified BioMarin, GC Biopharma and Hanmi Pharm as the parties to the transaction and identified HM15421/GC1134A as the therapy covered by the arrangement.

Worldwide scope for development and commercialization

The worldwide nature of the license agreement is a central element of the announcement. Thepharmaletter said BioMarin will develop and commercialize HM15421/GC1134A under the exclusive worldwide agreement with GC Biopharma and Hanmi Pharm.

For pharmaceutical and biotechnology commercial professionals, the news centers on a named investigational asset, a specific disease area and a worldwide development and commercialization mandate. The agreement connects BioMarin with GC Biopharma and Hanmi Pharm in support of work on a long-acting enzyme replacement therapy for Fabry disease.

Key points reported by Thepharmaletter

• BioMarin announced an exclusive worldwide license agreement.
• GC Biopharma and Hanmi Pharm are parties to the agreement.
• The therapy is HM15421/GC1134A.
• The asset is investigational and intended for Fabry disease.
• The stated activities are development and commercialization.

The supplied report does not provide additional terms of the agreement. The announcement, as reported by Thepharmaletter, focuses on the exclusive worldwide license and the parties’ plans to develop and commercialize HM15421/GC1134A.